Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1223)	7/15/2005 1:32:39 PM
From: Galirayo	Respond to of 3722

Bernard .. I have to place some retirement contributions .. I like this one. Have you found any better funds? Do you see any Weakness here? stockcharts.com[w,a]dacayiay[dd][pc20!b50!f][vc60][iut!Ua12,26,9!Uv25]&pref=G finance.yahoo.com finance.yahoo.com

To: Jibacoa who wrote (1223)	7/15/2005 1:38:54 PM
From: Jibacoa	Read Replies (1) \| Respond to of 3722

MNTA Has continued on the uptrend that started on June 16 from the 10 level. It has more than doubled since then in spite of the insiders selling and higher estimated losses for 2005 & 2006 <g> On June 16 it was announced that its generic version of Sanofis-Aventis' Lovenor could be launched if Sanofi loses its patent case.<g> Lovenox is a complex mixture of ingredients and reportedly it wont be easy for a generic company to make a similar compound, also it is questionable if the FDA would approveit.<g> However, MNTA has received some "upgrades" as Deutsche started coverage with "buy" recommendation and it presented at Bear Stearns Biotech Conference in Boston on June 28. MNTA Reportedly has around $1.98 in cash/shr and its Debt/Equt is around 0.03 but it had around $12.7M in negative cash flow from operations <g> Today it is up another 17% <g> bigcharts.marketwatch.com Bernard